Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Kinesio Taping für Lacertus-Syndrom

10. November 2026 aktualisiert von: Husam Taha, Arab American University (Palestine)

Die Wirksamkeit einer konservativen Behandlung mit zusätzlichem Kinesio Taping zur Verringerung von Schmerzen und Verbesserung der Handfunktion und Griffstärke bei Personen mit Lacertus-Syndrom: Eine Pilotstudie als randomisierte kontrollierte Studie

Background: Lacertus syndrome is a condition in which the median nerve is compressed at the lacertus fibrosus in the proximal forearm, leading to pain, numbness, weakness, and reduced hand function. The current standard treatment is surgical release. However, surgery may not be accessible or preferred by all patients, particularly in healthcare settings with limited resources. There is very little research on non-surgical treatment options for this condition.

Purpose: The purpose of this pilot study is to evaluate the feasibility and preliminary effectiveness of adding Kinesio Taping to a standardized conservative treatment program for adults diagnosed with lacertus syndrome.

Design: This is a single-blind, parallel-group, pilot randomized controlled trial with a 1:1 allocation ratio. Thirty adults aged 18 to 65 years with a confirmed diagnosis of lacertus syndrome will be randomly assigned to one of two groups: (1) an experimental group receiving therapeutic Kinesio Taping applied over the lacertus fibrosus in addition to standardized conservative treatment, or (2) a control group receiving standardized conservative treatment alone. The conservative treatment includes patient education, nerve gliding exercises, tendon gliding exercises, stretching, and activity modification. The intervention period is 4 weeks.

Outcomes: The primary outcomes are feasibility measures including recruitment rate, retention rate, and adherence to the Kinesio Taping protocol. Secondary outcomes include pain intensity measured by the Numeric Pain Rating Scale, upper extremity function measured by the Quick Disabilities of the Arm, Shoulder and Hand questionnaire, grip strength measured by a hydraulic hand dynamometer, and tip, key, and palmar pinch strength measured by a calibrated pinch gauge. All secondary outcomes are assessed at baseline and at 4 weeks.

Significance: This pilot study will provide essential data on the feasibility of conducting a Kinesio Taping intervention trial in the West Bank, Palestine, and will generate preliminary estimates of treatment effects to inform the design of a future definitive randomized controlled trial.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Background and Rationale

Lacertus syndrome is a dynamic compression of the median nerve at the lacertus fibrosus (bicipital aponeurosis) in the proximal forearm. It is often underdiagnosed and frequently misdiagnosed as carpal tunnel syndrome. Surgical release is the current standard of care, but surgery may not be accessible, feasible, or preferred by all patients, particularly in resource-constrained health systems, and no high-quality randomized controlled trials have evaluated non-surgical treatment for this condition. Systematic reviews and meta-analyses have shown that Kinesio Taping can reduce pain and improve function in carpal tunnel syndrome, another median nerve entrapment neuropathy, which provides a rationale for testing it in lacertus syndrome. The study is guided by the International Classification of Functioning, Disability and Health (Brief ICF Core Set for Hand Conditions), with Kinesio Taping viewed as a facilitator within the environmental factors domain.

Study Design

This is a pilot, single-blind, parallel-group randomized controlled trial with a 1:1 allocation ratio, designed following SPIRIT 2013 guidelines and reported according to the CONSORT extension for pilot and feasibility trials. The target sample of 30 participants (15 per group) follows established guidance for pilot and feasibility studies, which recommends samples of approximately 24 to 50 participants in order to estimate the standard deviation of candidate outcome measures with reasonable precision for planning a future definitive trial. The study will not be powered to detect statistically significant differences between groups; its purpose is to establish feasibility and to generate preliminary parameter estimates.

Setting and Recruitment

Participants will be recruited at two outpatient centers in the West Bank, Palestine, one in Ramallah and one in Nablus, where the collaborating hand surgeon practices. During routine clinical care, the hand surgeon will identify patients with suspected lacertus syndrome, establish the diagnosis, and confirm eligibility. He will then refer interested patients to the principal investigator, who will explain the study and obtain written informed consent in Arabic before the baseline assessment.

Allocation

After consent and the baseline assessment, participants will be allocated by covariate-adaptive minimization (Pocock and Simon method). The algorithm will balance age (40 years or younger versus older than 40), gender, symptom duration (4 to 12 weeks versus more than 12 weeks), baseline pain intensity (Numeric Pain Rating Scale score of 5 or less versus greater than 5), and recruitment site. A biased coin probability of 0.75 will favor the allocation that minimizes imbalance. Allocation will be carried out by the hand surgeon's clinic secretary, an administrative staff member with no role in diagnosis, treatment, or outcome assessment, using a spreadsheet that applies the minimization method. The secretary will tell the allocation only to the treating clinician at the participant's site.

Treating Clinicians

At each site, one treating clinician (an occupational therapist or physiotherapist with at least 3 years of musculoskeletal experience) will deliver all treatment described under Arms and Interventions, after a 90-minute orientation on the study protocols given by the principal investigator before recruitment begins.

Outcome Assessment and Blinding

Outcomes will be assessed at baseline, following enrollment and prior to group allocation, and at the end of the 4-week intervention period. The outcome assessor will be the principal investigator, who will have no role in diagnosis, allocation, or treatment. At each assessment, the assessor will first measure grip and pinch strength. Participants will then complete the pain and QuickDASH questionnaires on their own using an electronic form, without the assessor seeing their answers. The clinic secretary will keep the allocation list, the questionnaire data, and the adherence logs until all week-4 assessments are finished. Participants in the taping group will remove the tape 72 hours before the week-4 assessment and clean the skin, and all participants will be asked not to discuss their treatment with the assessor. Weekly follow-up calls and any contact about side effects will be handled by the treating clinicians, not by the assessor.

Data Analysis

Descriptive statistics will summarize feasibility outcomes and baseline characteristics. For secondary effectiveness outcomes, analysis will follow the intention-to-treat principle. Change scores from baseline to 4 weeks will be compared between groups using independent t-tests or Mann-Whitney U tests depending on data distribution (assessed by the Shapiro-Wilk test). Effect sizes (Cohen's d) with 95% confidence intervals will be calculated. A significance level of 0.05 will be used. Multiple imputation with 20 imputed datasets will handle missing data, with sensitivity analyses including complete case analysis, per-protocol analysis, and pattern mixture models.

Safety Monitoring

All participants will undergo skin patch testing prior to the first tape application. Adverse skin reactions will be classified using a standardized four-grade scale and managed per a predefined protocol. Participants will record skin reactions and other adverse events in a daily log, and the treating clinicians will ask about them during the weekly telephone calls. All adverse events will be documented and reported to the Institutional Review Board according to Good Clinical Practice guidelines.

Ethical Considerations

This study will be conducted in accordance with the Declaration of Helsinki and has been approved by the Institutional Review Board of the Arab American University of Palestine - Ramallah (approval number R-2026/A/15/N, approved February 3, 2026). All participants will provide written informed consent in Arabic prior to enrollment. All data will be anonymized to preserve participant confidentiality.

Changes to the Protocol (note added November 2026)

Before recruitment opened on April 1, 2026, some procedures were changed, mainly because the study had no funding for research staff or a web-based randomization system. The changes were reported to the Institutional Review Board before recruitment, but this description was only updated in November 2026, after the trial had ended. The original version stated that treating clinicians would refer patients and the principal investigator would screen them for eligibility; that an independent statistician would hold the allocation sequence in a password-protected web-based system; that participants would wear long sleeves during assessments; and that research staff would carry out weekly clinical assessments. The procedures actually used are described above. The protocol had also planned a research assistant as the outcome assessor; the principal investigator took this role instead. Because the masked investigator and the masked outcome assessor were the same person, masking was changed from "Double (Investigator, Outcomes Assessor)" to "Single (Outcomes Assessor)".

Studientyp

Interventionell

Einschreibung (Tatsächlich)

30

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Nablus, Palästinensische Gebiete
        • Al-Hakim Center
      • Ramallah, Palästinensische Gebiete
        • Elite for special orthopedic surgery

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults aged 18 to 65 years
  • Confirmed clinical diagnosis of lacertus syndrome established by a physician specializing in orthopedics, physical medicine, or neurology following a standardized multi-modal diagnostic protocol
  • Positive Hagert's triad, defined as the presence of all three of the following: (1) localized tenderness upon palpation of the lacertus fibrosus, (2) reproduction of symptoms during resisted forearm pronation, and (3) reproduction of symptoms during resisted elbow flexion
  • Positive Orthogonal Kinesiotaping Test (OKT) conducted by a trained examiner
  • Neurological evaluation excluding other median nerve entrapment syndromes such as carpal tunnel syndrome
  • Electrodiagnostic studies (electromyography and nerve conduction studies) confirming median nerve involvement and ruling out alternative sources of neural compromise including cervical radiculopathy
  • Symptom duration of at least 4 weeks to ensure subacute to chronic presentation
  • Willing and able to provide written informed consent
  • Able to attend all scheduled study visits and follow the home treatment protocol

Exclusion Criteria:

  • Previous surgery for lacertus syndrome or any other median nerve entrapment condition in the affected arm
  • Known allergy to Kinesio tape or adhesive materials
  • Dermatological condition at the intended site of tape application (e.g., open wounds, active skin infection, eczema, psoriasis)
  • Neurological disorder that could confound the assessment of lacertus syndrome symptoms (e.g., multiple sclerosis, diabetic peripheral neuropathy, cervical radiculopathy)
  • Musculoskeletal disorder in the affected upper extremity that could confound symptom assessment (e.g., lateral or medial epicondylitis, shoulder impingement, rheumatoid arthritis affecting the hand or wrist)
  • Current pregnancy
  • Receipt of corticosteroid injection for lacertus syndrome within the past 3 months
  • Current use of other therapeutic taping on the affected arm
  • Cognitive impairment that would prevent understanding of study procedures or self-application of Kinesio tape

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Kinesio Taping Plus Conservative Treatment

Participants in this arm will receive therapeutic Kinesio Taping applied with 25 to 50 percent stretch over the lacertus fibrosus region, using 5-centimeter-width elastic therapeutic tape following standardized anatomical landmarks (biceps tendon/lacertus fibrosus region, proximal pronator teres, and medial forearm fascia), reapplied every 2 to 3 days for 4 weeks. In addition, participants will receive the identical standardized conservative treatment protocol delivered to the comparator arm, including patient education, median nerve gliding exercises, tendon gliding exercises, forearm stretching exercises, activity modification guidelines, and weekly telephone follow-up

Therapeutic elastic Kinesio Tape (5 cm width) applied with 25 to 50 percent stretch over the lacertus fibrosus in the proximal forearm. The tape is applied following standardized anatomical landmarks: anchor placed without stretch over the medial epicondyle region, therapeutic zone applied with stretch directly over the lacertus fibrosus, and terminal anchor placed without stretch over the proximal forearm. The initial application is performed by a trained therapist in the clinic. Participants are trained for home reapplication through hands-on demonstration, printed step-by-step instructions, and an instructional video. Tape is reapplied every 2 to 3 days for a total of 4 weeks. Adherence is monitored using tape application logs.

A 4-week standardized conservative treatment protocol consisting of four components: (1) Education: a 30-minute session covering lacertus syndrome anatomy and pathophysiology, activity modification guidelines, and ergonomic principles, with written materials provided in Arabic; (2) Exercise program: median nerve gliding exercises (3 sets of 10 repetitions, twice daily), tendon gliding exercises for flexor tendons (3 sets of 10 repetitions, twice daily), and forearm muscle stretching (30-second holds, 3 repetitions, twice daily), with access to an instructional video; (3) Activity modification: avoidance of repetitive pronation for more than 30 minutes continuously, regular breaks every 30 minutes during repetitive activities, use of ergonomic tools, and specific workplace modifications; (4) Follow-up: standardized weekly telephone check-ins to monitor compliance and address questions, with exercise logs for tracking adherence.

Aktiver Komparator: Conservative Treatment Alone

Participants in this arm will receive the standardized conservative treatment protocol alone, consisting of a 30-minute educational session about lacertus syndrome, a structured home exercise program (median nerve gliding exercises, tendon gliding exercises, and forearm muscle stretching performed twice daily), activity modification guidelines, and weekly telephone follow-up. All study materials will be provided in Arabic.

A 4-week standardized conservative treatment protocol consisting of four components: (1) Education: a 30-minute session covering lacertus syndrome anatomy and pathophysiology, activity modification guidelines, and ergonomic principles, with written materials provided in Arabic; (2) Exercise program: median nerve gliding exercises (3 sets of 10 repetitions, twice daily), tendon gliding exercises for flexor tendons (3 sets of 10 repetitions, twice daily), and forearm muscle stretching (30-second holds, 3 repetitions, twice daily), with access to an instructional video; (3) Activity modification: avoidance of repetitive pronation for more than 30 minutes continuously, regular breaks every 30 minutes during repetitive activities, use of ergonomic tools, and specific workplace modifications; (4) Follow-up: standardized weekly telephone check-ins to monitor compliance and address questions, with exercise logs for tracking adherence.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Retention Rate
Zeitfenster: 4 weeks after baseline

The proportion of randomized participants who complete the full 4-week intervention period and the final outcome assessment. Calculated as the number of participants completing the study divided by the total number of randomized participants, expressed as a percentage.

4 weeks after baseline
Recruitment Rate
Zeitfenster: Through study completion, approximately 6 months

The number of eligible participants successfully enrolled into the study per month during the 6-month recruitment period. This will be calculated as the total number of randomized participants divided by the number of months of active recruitment.

Through study completion, approximately 6 months
Adherence Rate to Kinesio Taping Protocol
Zeitfenster: 4 weeks after baseline

The proportion of prescribed Kinesio Tape applications that were completed by participants in the experimental group, as documented in standardized tape application logs. Calculated as the number of actual tape applications divided by the number of expected applications over the 4-week intervention period, expressed as a percentage.

4 weeks after baseline

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Pain Intensity (Numeric Pain Rating Scale)
Zeitfenster: Baseline and 4 weeks

Change in pain intensity from baseline to 4 weeks measured using the Numeric Pain Rating Scale (NRS). The NRS is an 11-point scale ranging from 0 (no pain) to 10 (worst imaginable pain). A negative change score indicates improvement (pain reduction). The minimal clinically important difference is 2 points.

Baseline and 4 weeks
Change in Upper Extremity Function (QuickDASH)
Zeitfenster: Baseline and 4 weeks

Change in upper extremity function from baseline to 4 weeks measured using the Quick Disabilities of the Arm, Shoulder and Hand questionnaire (QuickDASH), Arabic validated version. The QuickDASH is an 11-item questionnaire scored from 0 (no disability) to 100 (most severe disability). A negative change score indicates improvement (reduced disability). The minimal clinically important difference is 8 to 16 points.

Baseline and 4 weeks
Change in Grip Strength
Zeitfenster: Baseline and 4 weeks

DescriptionChange in hand grip strength from baseline to 4 weeks measured using a calibrated hydraulic hand dynamometer following standardized protocols of the American Society of Hand Therapists. Measured in kilograms. The average of three trials with 30-second rest intervals will be recorded. A positive change score indicates improvement (increased strength)

Baseline and 4 weeks
Change in Tip Pinch Strength
Zeitfenster: Baseline and 4 weeks

Change in tip pinch strength from baseline to 4 weeks measured using a calibrated pinch gauge following standardized protocols of the American Society of Hand Therapists. Measured in kilograms. The average of three trials with 30-second rest intervals will be recorded

Baseline and 4 weeks
Change in Key (Lateral) Pinch Strength
Zeitfenster: Baseline and 4 weeks

Change in key (lateral) pinch strength from baseline to 4 weeks measured using a calibrated pinch gauge following standardized protocols of the American Society of Hand Therapists. Measured in kilograms. The average of three trials with 30-second rest intervals will be recorded.

Baseline and 4 weeks
Change in Palmar (Three-Jaw Chuck) Pinch Strength
Zeitfenster: Baseline and 4 weeks

Change in palmar (three-jaw chuck) pinch strength from baseline to 4 weeks measured using a calibrated pinch gauge following standardized protocols of the American Society of Hand Therapists. Measured in kilograms. The average of three trials with 30-second rest intervals will be recorded.

Baseline and 4 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. April 2026

Primärer Abschluss (Tatsächlich)

18. Juli 2026

Studienabschluss (Tatsächlich)

18. Juli 2026

Studienanmeldedaten

Zuerst eingereicht

3. Februar 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. Februar 2026

Zuerst gepostet (Tatsächlich)

12. Februar 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • R-2026/A/15/N

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Individual participant data that underlie the results reported in the published article will be shared, after de-identification. This includes demographic characteristics, baseline and post-intervention scores for all outcome measures (Numeric Pain Rating Scale, QuickDASH, grip strength, and pinch strength), group allocation, and adherence data.

IPD-Sharing-Zeitrahmen

Beginning 3 months after publication of the main study results and available for 5 years following publication.

IPD-Sharing-Zugriffskriterien

Researchers who provide a methodologically sound proposal for use of the data. Proposals should be directed to the principal investigator (Husam Omar Taha) at the Arab American University of Palestine. Requestors will be required to sign a data access agreement.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .